Anti-Doping Lab Qatar Seventh Annual Forum Concludes

04 May 2017
Anti-Doping Lab Qatar Seventh Annual Forum Concludes

The seventh annual forum of Anti-Doping Lab Qatar (ADLQ) held under the title "Anti-Doping in Humans and Animals: Parallels and Divergences" concluded here today.

The final day of the forum was attended by a large number of participants at the event. Director General of ADLQ Dr. Mohamed Al Serifi honored a number of the participating scientists and distinguished leading anti-doping personalities from around the world.

The day also included rich and varied discussion sessions, which were enriched by the participating doctors and scientists. The most prominent sessions were on experiments in the scientific and practical management of doping, and new techniques in the detection of doping especially in the field of sports.

The closing activities were attended by a number of scientists from the World Anti-Doping Agency (WADA), including Director of Science at the Agency Prof. Olivier Rabin and Deputy Director of Science Prof. Osquel Barroso, along with scientists, experts and doping specialists from inside and outside Qatar.

On the sidelines of the event, ADLQ held a press conference to announce a joint cooperation agreement with Metabolon Company, a globally leading company working in the field of metabolomics.

ADLQ will establish a platform for Metabolon's metabolomics to serve academic and non-profit organizations in 13 countries in the Middle East region.

The agreement will also allow ADLQ to promote Metabolon's technology for use in research, and to develop health studies for large populations throughout the region.

Anti-Doping Lab Qatar Director Dr. Mohamed Al Serifi commented saying that "this partnership was reinforced by the participation of both the Qatar Institute for Biomedical Research of Hamad bin Khalifa University and the Institute of Transitional Research at Hamad Medical Corporation." "The contributions made by our partners in the form of laboratory infrastructure devices have accelerated the utilization of Metabolon's advanced capabilities in metabolomics," he added.